

International Collaborative Ovarian Neoplasm studies (3): a trial of paclitaxel with carboplatin in the first-line treatment of ovarian cancer

Submission date 28/02/2001	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 28/02/2001	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 09/07/2014	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Ms Claire Amos

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
ICON3

Study information

Scientific Title

Study objectives

To compare paclitaxel in combination with carboplatin versus a control treatment of either single-agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin) as first-line treatment of patients with advanced ovarian cancer.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Cancer

Interventions

1. One group receives paclitaxel in combination with carboplatin
2. The other group receives a control treatment of either single-agent carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin)

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Paclitaxel, carboplatin, cyclophosphamide, doxorubicin, cisplatin

Primary outcome measure

Survival time - time to progression, quality of life, health economics

Secondary outcome measures

Not provided at time of registration

Overall study start date

27/03/1995

Completion date

01/06/1998

Eligibility

Key inclusion criteria

1. Chemotherapy indicated
2. No previous chemotherapy or radiotherapy
3. No contraindication to chemotherapy

Participant type(s)

Patient

Age group

Not Specified

Sex

Female

Target number of participants

2000

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

27/03/1995

Date of final enrolment

01/06/1998

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent
London
United Kingdom
W1B 1AL
+44 (0)20 7636 5422
clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

<http://www.mrc.ac.uk>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	17/08/2002		Yes	No